Lupus drug anifrolumab put to the test in everyday patients
NCT ID NCT07215754
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows 300 people with active systemic lupus erythematosus (SLE) who are taking anifrolumab, a drug that blocks a key immune signal. Researchers will track how many achieve remission or low disease activity over 5 years, as well as side effects and quality of life. The goal is to see if the drug works as well in real-world clinics as it did in earlier trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anifrolumab
What this could lead to
If successful, this study could confirm that anifrolumab helps more lupus patients achieve remission or low disease activity with fewer steroids in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage real-world evidence, and the drug may not work as well outside clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pisa
RECRUITINGPisa, 56100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••